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ABSTRACT
Introduction: Lipohypertrophy (LH) is a com-
mon complication occurring in diabetes indi-
viduals. The most common methods used
include palpation, visual examination and/or
ultrasound (US). To date, there is limited
information on the detection sensitivity among
the different techniques used to identify LH.
This systematic review aimed to identify studies
that examined insulin-related LH using US
detection to identify the prevalence, character-
istics and morphology of LH, and to compare
US and clinical palpation methods for detecting
LH.
Methods: Three electronic databases were sys-
tematically searched for studies detecting LH
using US in insulin users. Articles were screened
for eligibility and included studies were
appraised using quality assessment tools. The
quality of the evidence was evaluated using
Grading of Recommendations Assessment,
Development and Evaluation, and the extracted
data was synthesised narratively.
Results: Sixteen articles were included in the
review providing data on 1722 patients. The
prevalence of LH prevalence varied from 14.5%
to 88% (median 56.6%). Identified risk factors
for the development of included insulin injec-
tion behaviour such as a lack of injection site
rotation and social factors such as low educa-
tion level. Four studies compared LH detection
by US to palpation, providing inconsistent
results. One study showed that palpation
detected 64% more LH, whilst two studies
demonstrated that US identified 50% more sites
and extended areas of LH (additional * 5 cm2).
Another study provided comparable estimates
between palpation and US in clinicians trained
to detect LH (97%).
Conclusion: The evidence highlights a lack of
congruence in results pertaining to the detec-
tion sensitivity of US and palpation for LH sites.
More research with robust study design is nee-
ded to verify whether clinically palpation is
sufficient to detect LH, or whether US would
increase the precision of LH assessment to help
address this common clinically significant
problem.
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INTRODUCTION
Lipohypertrophy (LH) occurs in subcutaneous
tissue as a result of the lipogenic effect of repe-
ated insulin exposure [1, 2]. The fat cells enlarge
and proliferate resulting in thickened tissue,
sometimes forming lumps under the skin. LH is
associated with suboptimal glycaemic control,
with one recent study reporting a threefold
higher incidence of LH in patients whose con-
trol was above the current national target
(HbA1c C 7%, 86 mmol/L), compared to those
within the target range [3]. Injecting insulin
into an LH lesion has been shown to attenuate
insulin action with consequent excess glucose
exposure, glycaemic variability and increased
risk of severe hypoglycaemia [4–6]. Known risk
factors for the development of LH include high
BMI (C 25), frequent needle reuse, failure to
rotate insulin injection sites effectively, size of
rotation area, level of education, and duration
of insulin exposure [3, 7, 8]. It is also likely that
patient behaviours are significant mediators in
the level of LH observed, with patients reusing
sites that are less painful or because a site is
more convenient to access [9, 10].
Increasing awareness of the importance of
LH in diabetes care has led to the development
of international guidelines for managing injec-
tion areas and for detecting LH [11, 12]. One
recent multicentred UK study demonstrated
improved injecting behaviours and metabolic
outcomes following implementation of one of
these guidelines in about two thirds of those
exposed to the guideline [13]. However, the
extent to which these guidelines are observed in
routine clinical care is unknown, nor is it
known how frequently or rigorously LH is
assessed. It may be that there is a lack of
awareness within the community of diabetes
professionals and patients on the prevalence
and significance of LH.
In clinical practice, LH is most commonly
assessed by palpation. However, the reliability
of this method is potentially low, with high
levels of inter-clinician variation. This was
recently demonstrated by Gentile et al. [14],
whereby nurses trained to use a more stringent
palpation technique were able to show 97%
detection of cases; while the comparator missed
34% of cases. As a consequence, ultrasound (US)
has been proposed as a potentially more objec-
tive method for detecting LH. US may provide
more precise estimates of the true prevalence of
LH, as current estimates based on mainly
observation or palpation are divergent with
estimates ranging from 3.6% to 64%, with a
median of 32.8% [14].
The aim of this systematic review was to
present a summary of the additional insights
into LH contributed by US detection studies by
assessing the prevalence of LH, identifying fac-
tors associated with the development of LH, and
providing some estimation on the sensitivity of
palpation versus US in detecting LH.
METHODS
A protocol-based systematic review was used to
identify studies using US to detect LH, address-
ing the following objectives:
• To identify the estimated prevalence,
anatomical distribution and the tissue mor-
phology of LH with US and/or palpation
assessment
• To identify factors associated with LH in US
assessed cases
• To estimate the sensitivity of palpation in LH
detection, with US as the reference
Search Strategy
A comprehensive literature search was con-
ducted using three electronic databases (Med-
line, Embase and Cinahl) to identify articles
pertaining to the detection of LH using US in
insulin-treated patients with diabetes mellitus.
The search used both Medical Subject Headings
(MeSH) and free-text synonyms for the follow-
ing terms: palpation, ultrasonography, lipodys-
trophy, diabetes mellitus and insulin. An
example search protocol is presented in
Appendix 1. Additional papers were identified
through free-text searches, citation searching
and by reviewing secondary references.
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Retrieved articles were screened by three inde-
pendent researchers for their relevance (HA, RH
and RD).
Selection Criteria
Studies examining the detection of LH using US
with or without palpation techniques in type 1
and type 2 insulin-treated patients with dia-
betes were included in the literature synthesis.
Publications were excluded if they discussed LH
in the context of gestational diabetes, were
based on visual examination only without pal-
pation, or addressed other causes of lipodystro-
phy. Only data from primary studies were
considered and review articles were excluded.
Data Extraction
Two review authors (HA, RD) independently
extracted the data from the included studies.
The main outcomes reviewed were the different
forms of insulin administration resulting in LH
occurrence, risk factors of LH and the detection
sensitivity of LH using US and/or palpation.
Additional data extracted included study
design, study location and year, population,
sample size, insulin exposures, patient charac-
teristics and metabolic factors.
Data Synthesis
The data were synthesised using a narrative
approach addressing the outlined review
objectives. Studies were too heterogeneous to
provide a meta-analysis, but study results were
tabulated to provide a collective assessment of
their findings.
Quality Assessment
The relevant studies identified for inclusion in
the review used different methods and designs;
hence, multiple appraisal tools were used to
assess the scientific rigour and quality of the
studies, including the Cochrane Collaboration
tool for randomised controlled trials (RCTs)
[15], the Quality Assessment Tool for
Observational Cohort and Cross-Sectional
Studies devised by the National Institutes of
Health [16], and the Joanna Briggs Institute
critical appraisal checklist for case reports [17].
Two authors assessed the overall quality of the
included studies (HA, RD). The Grading of
Recommendations Assessment, Development
and Evaluation (GRADE) approach was also
employed to assess the quality of the estima-
tions provided by the included studies, consid-
ering the following criteria: risk of bias;
inconsistency, indirectness and imprecision;
effect magnitude; dose–response effect; and
other sources of potential confounders. The
quality assessments were used to rate the quality
of the evidence from high to very low [18].
Ethical Considerations
This article does not contain any new studies
with human or animal subjects performed by
any of the authors and as such no ethical
approval was required.
RESULTS
The search strategy yielded 317 citations,
duplicates were removed and the remaining
articles were subsequently screened for their
relevance based on the review inclusion criteria
(n = 284). Reasons for exclusion included
detection method not identified (n = 5), study
did not address the review objectives (n = 4), or
repetition of findings in multiple papers (n = 4).
A total of 17 unique studies reported in 16
papers were selected for inclusion (Fig. 1).
The characteristics of the studies included in
the literature synthesis are presented in Table 1.
Most studies utilised observational designs to
consider the frequency of LH in cohorts of
insulin-treated patients [14, 19–30]. Four studies
compared the detection sensitivities of palpation
and using US as a reference standard
[14, 19, 23, 29, 31]. Three individual cases of LH
in patients with diabetes were presented [20, 32]
and one considered the effectiveness of LH
detection using three different methods using a
cross-over RCT design [4]. A few studies pre-
sented data on glycaemic control and insulin
Diabetes Ther (2018) 9:1741–1756 1743
activity following insulin administration in LH
regions [4, 19, 20, 32] and risk factors in pro-
moting LH lesions [20–22, 25, 26]. Three studies
aimed to define and grade LH using US scanning
[19, 24, 33]. Across the studies, insulin exposure
was almost exclusively via needle injection.
Thirteen studies were carried out in Europe, and
two each in North America and Asia.
Quality Appraisal
The overall quality of the observational studies
was poor, with information deficits in relation
to the power of the analyses undertaken and
level of follow-up. Of the studies comparing
palpation and US, only two mentioned blinding
and only three out of the 12 observational
studies were adjusted for confounders. Despite
the overall poor quality of the studies, they all
yielded data of relevance to the review objec-
tives. The RCT study was identified as having a
moderate rating for risk of bias, as there was a
lack of information on allocation concealment
and participant blinding which may have led to
assessor contamination [4]. The findings of the
review are presented thematically below, with
tables summarising the study findings.
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Fig. 1 PRISMA ﬂowchart for inclusion of selected articles in this systematic review
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LH Prevalence, Anatomical Distribution
and Tissue Morphology
Nine studies assessed the prevalence of LH
lesions. The prevalence of LH ranged from
14.5% to 88%, with a median estimate of 56.6%
(Table 2). Two studies considered prevalence in
the context of continuous subcutaneous insulin
infusion (CSII) delivery and reported respective
prevalences of 44% and 76% [21, 26].
Seven studies examined the anatomical dis-
tribution of LH sites, with the abdomen, thighs
and arms being the most frequently identified
(Table 3). Less common areas were the back,
buttocks and hips [14, 19–21, 23, 25, 29].
Characterisation of LH Using US
In terms of tissue morphology, the reported
characteristics showed mainly increased
echogenicity in diffuse areas of the injected
subcutaneous tissue, some with clearly defined
nodules of different sizes embedded within the
area with circumscribed margins
[19, 24, 27, 28, 33]. Kapeluto et al. [33] define
this further as nodules not having a capsule or
vascularity, which differentiates the US signa-
ture of LH from haematomas or fluid-filled
cysts, which do have capsules. In some cases,
the centre or part of these LH nodules could be
hypoechogenic possibly representing fluid from
oedema or fat necrosis [19, 27, 28]. Perciun and
Mihu [28] also showed reduced echogenicity
when the sites had been rested for 6 months,
suggesting dissipation of the LH, but not in all
cases and particularly not in those showing
greater fibrosis of the fat tissue (echogenicity),
or in those with possible necrosis at baseline
scan. The study by Perciun and Mihu [28],
which included 10 children (19% of the
cohort), reported the presence of LH in cases
with insulin exposure of as little as 2–5 months.
Thickening of the dermal layer and loss of a
clear delineation between the subcutaneous and
dermal layer at the injection site was noted in
two papers and was identified as a potential
inflammatory response to repeated insulin
exposure [24, 27].
Four studies attempted to classify LH into
types or grades of LH [19, 24, 27, 33]. Perciun
[27] included five levels for LH grading: (1)
nearly normal, (2) diffuse echogenicity (fibrous
tissue) with no well-defined delineation
between dermis and subcutis, (3) focal areas
within this tissue (nodules within diffuse areas),
(4) focal areas with hypoechogenic halos within
the nodules, a thickened dermal layer and loss
Table 2 Prevalence of LH depicted by different detection methods
Author (year) Insulin therapya LH prevalence (%) based on detection method
US Palpation Not speciﬁed
Blanco et al. (2013) [20] Pen 64.4
Conwell et al. (2008) [21] CSII 44.0
Davidenko et al. (2014) [22] NS 84.0
Gentile et al. (2016) [14] Needle injection 48.8
Nasser et al. (2017) [25] Needle injection 36.8
Patrakeeva et al. (2014) [26] CSII, MDI 76.0
Perciun (2010) [27] Needle injection 88.0
Volkova et al. (2013) [29] Needle injection 86.5 37.0
Wang et al. (2014) [30] Needle injection 14.5
CSII continuous subcutaneous insulin infusion, LH lipohypertrophy, MDI multiple dose injection, US ultrasound
a Primary or longest mode of insulin delivery
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of delineation between the dermis and subcutis
layers, (5) nodules with a hypoechogenic
necrotic or liquid-filled areas and thickened
dermis. More recently, Mulnier et al. [24] fur-
ther identified a four-level grading scale of LH
based on the presence of diffuse areas, nodule
size, nodule number and inflammatory chan-
ges. Bertuzzi et al. [19] characterised LH on the
basis of hyperechogenic regions with prevailing
fibrosis, hypoechogenic areas and mixed hypo/
hyperechogenicity.
Risk Factors of LH
Five studies considered associations between
injecting behaviours and patient characteristics
with the presence of LH (Table 4). These find-
ings suggest higher prevalence of LH in relation
to the level of site rotation, frequency of injec-
tions, needle reuse, needle injection at 90,
injection in the arm and abdomen, and a lower
level of general education.
Sensitivity of LH Detection Methods
Four studies compared physical assessment of
LH with US detection. The methods used for
physical examination varied and included both
visualisation and different palpation protocols.
Only one of four studies used prespecified cri-
teria to examine areas of LH, including either
features of hyperechogenic (fibrosis) or
Table 3 Regional distribution of LH
Author (year) Insulin
therapya
Anatomical distribution of LH
Abdomen Arm Thigh/gluteus Other
Bertuzzi et al. (2017)
[19]
CSII, MDI 100% (US,
Palp.)
25.0% (US),
20.0% (Palp.)
25.0% (US),
20.0% (Palp.)
Blanco et al. (2013)
[20]
Pen NDb
Conwell et al. (2008)
[21]
CSII SS:
6.1 ± 3.3
SS: 4.9 ± 4.2
Gentile et al. (2016)
[14]
Needle
injection
40.0% 35.0% 25.0%
Kasperska-Czyzyk et al.
(2000) [23]
Needle
injection
61.8% 17.6% 20.6%
Nasser et al. (2017)
[25]
Needle
injection
S/SC: 3.1/
23.3 mm
S/SC: 2.9/
12.3 mm
S/SC: 3.2/
12.3 mm
Volkova et al. (2013)
[29]
Needle
injection
Paraumbilical/buttocks:
61.0%
Paraumbilical/
buttocks ? hips: 15.0%
Paraumbilical/
buttocks ? shoulders:
11.0%
CSII continuous subcutaneous insulin infusion, LH lipohypertrophy, MDI multiple dose injection, ND no data, Palp.
palpation, S/SC skin/subcutaneous thickness, SS severity score, US ultrasound
a Primary or longest mode of insulin delivery
b Authors report that LH sites were most commonly observed in the abdomen
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hypoechogenic (oedema/fluid) lesions [19];
whilst the remaining studies were preliminary
and did not mention their protocol in detail.
The methods used for palpation detection of LH
varied considerably and included a palpable
increase in subcutaneous fat [23], an extended
version of the FIT guidelines involving a pinch
technique to compare the thickness of harder
skin to adjacent areas of skin [14], and another
examined the shape irregularity of LH areas, as
well as assessing texture consistency and area of
LH extension [19]. As a result of inconsistences
in protocol design in detection tools across the
studies, the estimations of LH prevalence varied
between studies. One study reported that pal-
pation detected 64%more LH regions compared
to US [23]. Conversely, Volkova et al. [29]
reported that US scanning detected 56% more
LH lesions than with palpation alone. One
study included a comparison between routine
palpation and palpation by nurses trained to
identify LH lesions through a detailed stringent
tactile palpation technique with US [14]. They
found that while standard palpation methods
detected 66% of the US identified lesions, the
additionally trained nurses detected 96% of
lesions. The fourth study identified overall
equivalence in the detection of LH between US
and palpation [19]. However, they found that
US was able to detect more sites in the arm and
gluteus regions than palpation [19]. This study
also reported high precision in the US-assessed
LH region in relation to the size and distribu-
tion of the affected areas. The area of lipohy-
pertrophic extensions was noted to be 5 cm2
bigger with US (* 35 ± 10 cm2) than that
recorded by palpation and inspection
(* 30 ± 15 cm2), suggesting increased sensi-
tivity [19].
DISCUSSION
This is the first systematic review of studies of
US assessed LH. The review has identified some
potentially important new insights into the
distribution and characteristics of LH based on
US examination. In terms of regional distribu-
tion, LH was predominantly localised in the
abdomen, a finding consistent with palpation
and possibly associated with patient preference
for the abdomen as an injection site. The studies
Table 4 Risk factors of LH
Author (year) Risk factors of LH Statistical value
Blanco et al. (2013) [20] Needle reuse
Patient-reported injection site rotation
Nurse-reported injection site rotation
Nurse observed ? patient claimed injection site rotation
P = 0.008
P = 0.001
P = 0.0001
P = 0.0001
Conwell et al. (2008) [21] BMI z-score 0.60 ± 0.76
Needle insertion angle at 908
r = - 0.3, P = 0.04
P = 0.03
Davidenko et al. (2014) [22] Insulin use AUC[ 0.5–86.0%
Nasser et al. (2017) [25] Level of education
Number of injections
Injection site: Arm
Injection site: Abdomen
P = 0.02
P = 0.02
P = 0.04
P = 0.001
Patrakeeva et al. (2014) [26] Glucose variability
Incorrect insulin injection technique/infusion set changing
r = 0.8
r = 0.7
AUC area under the curve, BMI body mass index, LH lipohypertrophy
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using US to characterise LH provide a much
more detailed perspective on the size and depth
of tissue changes observed following repeated
insulin exposure and available tissue, suggesting
that US could be used to optimise needle length
selection.
Findings relating to the comparison between
palpation and US for LH sites illustrate a dis-
crepancy in the detection of these sites with one
study reporting that palpation produces 65%
more false positive results [23], while another
demonstrates that US detects 50% more LH
cases [29]. It is conceivable that deficits in LH
detection reported for palpation are related to
inadequate technique. While more rigorous
guidelines have been established, most notably
the FIT guideline in 2010 [34] which are
observed in many countries [35], it was noted
that this approach was inferior to an even more
rigorous method of palpation with a 60%
higher rate of detection [14]. This result may
suggest that a rigorous palpation method may
be as sensitive as US and if adopted clinically
would limit the need to use US in clinical care.
However, US has additional advantages over
palpation as it can better assign the nature and
severity of LH in much more detail compared to
palpation, enabling greater granularity in grad-
ing the LH (size, distribution and elasticity)
[19, 24, 28, 33] and thus giving clinicians the
opportunity to give more detailed advice to
patients. Through visualisation of the LH tissue,
US images may encourage injection behaviour
changes by revealing areas of disrupted tissue,
inflammation and depth of subcutaneous tis-
sue. This could help inform choice of needle
length and reinforce the importance of site
rotation and single needle use. Future detailed
clinical studies of the impact of the differing
types and grades of LH on the insulin action
curve and glucose variability could be highly
valuable and informative clinically. From a
behaviour change perspective, the patient
visualising the injection sites on US may act as a
strong cue to move sites as well as choose
appropriate needle lengths and new injection
areas with optimal insulin absorption and
action. Overall, the use of US could encourage
and reinforce injection techniques, which could
support and improve effective self-management
of diabetes and help minimise the risk of long-
term complications. Finally, the incorporation
of US into routine clinical care in the context of
the annual review may ensure that LH is
screened more objectively, precisely and
rigorously.
Strengths and Limitations
As with all reviews, the level of insight gained is
predicated by the quality of the evidence and
methods of the source studies. There are some
shortcomings in the quality of the included
studies. A particular weakness was in relation to
the studies comparing palpation and US in LH
assessment, where there was a high level of
heterogeneity in the detection methods
observed which may confound the results.
Moreover, the lack of detail on the clinician’s
training level to detect LH may affect the
validity of the findings. However, we were able
to extrapolate from these studies some impor-
tant insights into LH by integrating the study
findings. Nonetheless, this review has high-
lighted some important details on the nature of
LH and the potential of US in its detection and
management, paving the way for further
inquiry into this important and neglected
aspect of diabetes care.
Implications for Future Research
Currently, there are limited studies that present
data on LH detection accuracy from palpation
and US assessment. Conducting RCTs that
include nurse training to implement the
extended FIT guidelines for palpation tech-
niques and interpretation of echogenic US scans
of LH sites would provide more credible com-
parative results on the reliability and sensitivity
of each detection method. In addition, eco-
nomic evaluation of the diagnostic sensitivity
of the different methods would ascertain the
cost-effectiveness of each. Lastly, information
on staff and patients’ experiences of LH detec-
tion and site management in the avoidance of
LH could help us better understand patient
injection preferences as well as design a site
management method that would help avoid the
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build-up of LH and help prevent it in those new
to treatment with insulin in the future.
CONCLUSION
The current literature emphasises the knowl-
edge gap in the sensitivity, reliability and
accuracy of the different tools used to detect the
presence of LH. The existing research highlights
the need for further and more robust clinical
research to evaluate the feasibility and cost-ef-
fectiveness of US in comparison to palpation.
Nonetheless, the overall evidence implicates
that US scans may provide more accurate results
than palpation alone and can report more
explicit detailed information that could prompt
effective education on injection and site man-
agement practices that could potentially
improve self-management and diabetes out-
comes. The dynamic shift to e-health aimed at
improving efficiency and accuracy suggests that
introduction of US scanning for LH assessments
in routine care is foreseeable.
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